Sign in
  • NFT
  • Crypto
  • Stocks
  • DeFI
  • KNIGHTS
  • Luxury
  • Trade
  • Horse Racing
  • Travel
  • Crypto Caps
Sign in
Welcome!Log into your account
Forgot your password?
Privacy Policy
Password recovery
Recover your password
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
A password will be e-mailed to you.
Live Trading News Live Trading News
Knights App
Live Trading News Live Trading News
  • NFT
  • Crypto
  • Stocks
  • DeFI
  • KNIGHTS
  • Luxury
  • Trade
  • Horse Racing
  • Travel
  • Crypto Caps
Home Headline News Jaguar Health (NASDAQ:JAGX) Stock Is on the Move
  • Headline News
  • Investments
  • Opinion
  • Shayne Heffernan
  • Stocks
  • Top Stories
  • US Stocks

Jaguar Health (NASDAQ:JAGX) Stock Is on the Move

By
S. Jack Heffernan Ph.D
-
January 6, 2021
Facebook
Twitter
Pinterest
WhatsApp

    $JAGX #JaguarHealth #USA #Stocks #Nasdaq #Market #Trading

    Jaguar Health
    Ticker: NASDAQ:JAGX
    Price: $1.95

    Jaguar Health News

    Jaguar Health is a California-based biopharmaceutical company that specializes in treating gastrointestinal conditions. It focuses on both humans and animals, although its treatments for two-legged patients are farther along in the pipeline. In fact, news that it was hoping to expand the use of its drug Mytesi is what sent JAGX stock soaring in December.

    With that in mind, here are a few things to know about Jaguar Health:

    • Jaguar Health says it focuses on developing sustainably derived gastrointestinal products. Specifically, it looks to develop plant-based prescription medicines.
    • The company also has a wholly owned subsidiary, Napo Pharmaceuticals.
    • Napo specifically works to develop and commercialize treatments based on rainforest-area plants.
    • Investors should note that the main Jaguar product is Mytesi, which has U.S. Food and Drug Administration approval.
    • Right now, Mytesi is used as an antidiarrheal in adult patients with HIV/AIDS who are on antiretroviral therapies.
    • Earlier in December, Jaguar Health announced a new financing deal to help fund a few regulatory actions.
    • Importantly, Jaguar Health thinks Mytesi works as an antidiarrheal for other conditions.
    • Specifically, it is hoping to receive regulatory approval to market Mytesi as an antidiarrheal for cancer therapy-induced diarrhea.
    • Napo Pharmaceuticals is also making big moves.
    • Specifically, the company is working to expand into Europe as Napo EU.
    • There, Napo Pharmaceuticals is also discussing a SPAC merger to take its new Napo EU public.
    • Additionally, Napo Pharmaceuticals believes Mytesi could potentially work as an antidiarrheal for patients with long-term Covid-19 symptoms.

    Business Summary

    Jaguar Health, Inc. is a natural-products pharmaceuticals company.

    The Company is focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis.

    The Company, through its subsidiary Napo Pharmaceuticals, Inc., is focused on developing and commercializing human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.

    Its Mytesi is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with human immunodeficiency virus HIV/ acquired immune deficiency syndrome (AIDS) on antiretroviral therapy. Its other products include Canalevia, Equilevia, Neonorm Calf and Neonorm Foal.

    Price Performance

    Relative Valuation

    Technical Indicators

    Overall, the bias in prices is: Upwards.

    Note: this chart shows extraordinary price action to the upside.

    By the way, prices are vulnerable to a correction towards 0.55.

    The projected upper bound is: 2.51.

    The projected lower bound is: 1.45.

    The projected closing price is: 1.98.

    Candlesticks

    A black body occurred (because prices closed lower than they opened).
    During the past 10 bars, there have been 5 white candles and 5 black candles. During the past 50 bars, there have been 17 white candles and 33 black candles for a net of 16 black candles.

    A long upper shadow occurred. This is typically a bearish signal (particularly when it occurs near a high price level, at resistance level, or when the security is overbought).

    A rising window occurred (where the top of the previous shadow is below the bottom of the current shadow). This usually implies a continuation of a bullish trend. There have been 3 rising windows in the last 50 candles–this makes the current rising window even more bullish.

    Momentum Indicators

    Momentum is a general term used to describe the speed at which prices move over a given time period. Generally, changes in momentum tend to lead to changes in prices. This expert shows the current values of four popular momentum indicators.

    Stochastic Oscillator

    One method of interpreting the Stochastic Oscillator is looking for overbought areas (above 80) and oversold areas (below 20). The Stochastic Oscillator is 66.5375. This is not an overbought or oversold reading. The last signal was a buy 13 period(s) ago.

    Relative Strength Index (RSI)

    The RSI shows overbought (above 70) and oversold (below 30) areas. The current value of the RSI is 82.39. This is where it usually tops. The RSI usually forms tops and bottoms before the underlying security. A buy or sell signal is generated when the RSI moves out of an overbought/oversold area. The last signal was a sell 6 period(s) ago.

    MACD

    The Moving Average Convergence/Divergence indicator (MACD) gives signals when it crosses its 9 period signal line. The last signal was a buy 7 period(s) ago.

    Rex Takasugi – TD Profile

    JAGUAR HELTH ORD closed up 0.170 at 1.950. Volume was 897% above average (trending) and Bollinger Bands were 564% wider than normal.

    Open    High    Low    Close    Volume
    2.210   2.990   1.890  1.950    334,251,584
    Technical Outlook
    Short Term:        Neutral
    Intermediate Term: Bullish
    Long Term:         Bullish
    Moving Averages: 10-period     50-period      200-period
    Close:           0.92          0.40           0.46
    Volatility:      745           409            234
    Volume:          182,419,424   55,348,944     17,208,800

    Short-term traders should pay closer attention to buy/sell arrows while intermediate/long-term traders should place greater emphasis on the Bullish or Bearish trend reflected in the lower ribbon.

    Summary

    JAGUAR HELTH ORD gapped up today (bullish) on heavy volume. Possibility of a Breakaway Gap which usually signifies the beginning of a major market move. Four types of price gaps exist – Common, Breakaway, Runaway, and Exhaustion. Gaps acts as support/resistance.

    JAGUAR HELTH ORD is currently 319.6% above its 200-period moving average and is in an upward trend. Volatility is extremely high when compared to the average volatility over the last 10 periods. There is a good possibility that volatility will decrease and prices will stabilize in the near term. Our volume indicators reflect very strong flows of volume into JAGX.O (bullish). Our trend forecasting oscillators are currently bullish on JAGX.O and have had this outlook for the last 24 periods. Our momentum oscillator is currently indicating that JAGX.O is currently in an overbought condition. The security price has set a new 14-period high while our momentum oscillator has not. This is a bearish divergence.

    • TAGS
    • best fx account
    • best fx company
    • best trading platform
    • daily stock brief Heffx
    • Make money trading with Heffx
    • morning call with Heffx
    • open an account fx
    • Shayne Heffernan well known economist Asia
    • trade like Shayne Heffernan
    Facebook
    Twitter
    Pinterest
    WhatsApp
      Previous articleNaked Brand Group (NASDAQ:NAKD) Shares Are Experiencing Heavy Trading
      Next articleGreenbriar Capital Corp. (TSXV: GRB) (OTC Pink: GEBRF) News
      S. Jack Heffernan Ph.D
      https://www.knightsbridge.law
      S. Jack Heffernan Ph.D. Economist at Knightsbridge holds a Ph.D. in Economics and brings with him over 25 years of trading experience in Asia and hands on experience in Venture Capital, he has been involved in several start ups that have seen market capitalization over $500m and 1 that reach a peak market cap of $15b. He has managed and overseen start ups in Crypto, Mining, Shipping, Technology and Financial Services.

      RELATED ARTICLESMORE FROM AUTHOR

      Bitcoin-Legal
      2023

      Arizona Senator Bill to make Bitcoin Legal Tender

      NFT

      Search for Animera WEB3 Experience

      Binance

      Milo Launches Crypto Loans


      Live Trading News
      Your Trusted Source For All Crypto and Stocks Related News
      Contact us: [email protected]

      EVEN MORE NEWS

      Why you should own FBX?

      January 26, 2023

      Deribit next destination: Dubai

      January 26, 2023
      Bitcoin-Legal

      Arizona Senator Bill to make Bitcoin Legal Tender

      January 25, 2023

      POPULAR CATEGORY

      • Headline News7509
      • Investments7149
      • Top Stories6228
      • Paul Ebeling5633
      • Shayne Heffernan4495
      • Shayne Heffernan4376
      • Stocks4110
      • About us
      • Advertise
      • Send us a tip!
      • Write a review
      • Contact us
      © LiveTradingNews
      MORE STORIES

      Bitcoin: USD/BTC (BTC=X) approaching the critical $6,800 level of resistance after...

      March 25, 2020

      F1: Ferrari (NYSE:RACE) to Bring SF1000 Updates Nurburgring

      October 1, 2020

      Christmas Star Meditation December 21, 2020

      December 19, 2020
      CLOSE